A
Andrea Anichini
Researcher at Vita-Salute San Raffaele University
Publications - 174
Citations - 10851
Andrea Anichini is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Melanoma & Antigen. The author has an hindex of 54, co-authored 164 publications receiving 9767 citations. Previous affiliations of Andrea Anichini include Istituto Superiore di Sanità.
Papers
More filters
Journal ArticleDOI
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano,Roberta Frapolli,Cristina Belgiovine,Achille Anselmo,Samantha Pesce,Manuela Liguori,Eugenio Erba,Sarah Uboldi,Massimo Zucchetti,Fabio Pasqualini,Manuela Nebuloni,Nico van Rooijen,Roberta Mortarini,Luca Beltrame,Sergio Marchini,Ilaria Fuso Nerini,Roberta Sanfilippo,Paolo G. Casali,Silvana Pilotti,Carlos M. Galmarini,Andrea Anichini,Alberto Mantovani,Maurizio D'Incalci,Paola Allavena +23 more
TL;DR: It is demonstrated that trabectedin, a recently approved chemotherapeutic agent, induces rapid apoptosis exclusively in mononuclear phagocytes, and this unexpected property may be exploited in different therapeutic strategies.
Journal ArticleDOI
Interleukin-12: biological properties and clinical application.
Michele Del Vecchio,Emilio Bajetta,Stefania Canova,Michael T. Lotze,Amy Wesa,Giorgio Parmiani,Andrea Anichini +6 more
TL;DR: More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.
Journal ArticleDOI
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study
Andrea Necchi,Andrea Anichini,Daniele Raggi,Alberto Briganti,Simona Massa,Roberta Lucianò,Maurizio Colecchia,Patrizia Giannatempo,Roberta Mortarini,Marco Bianchi,Elena Farè,Francesco Monopoli,Renzo Colombo,Andrea Gallina,Andrea Salonia,Antonella Messina,Siraj M. Ali,Russell Madison,Jeffrey S. Ross,Jon Chung,Roberto Salvioni,Luigi Mariani,Francesco Montorsi +22 more
TL;DR: It is indicated that pembrolizumab could be a worthwhile neoadjuvant therapy for the treatment of MIBC when limited to patients with PD-L1-positive or high-TMB tumors.
Journal ArticleDOI
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Giorgio Parmiani,Chiara Castelli,Piero Dalerba,Roberta Mortarini,Licia Rivoltini,Francesco M. Marincola,Andrea Anichini +6 more
TL;DR: The available human TAA peptides, the potential immunogenicity (i.e., the ability to trigger a tumor-specific T-cell response) of T AA peptides in vitro and ex vivo, and the potential to construct slightly modified forms of Taa peptides that have increased T- cell stimulatory activity are analyzed.
Journal ArticleDOI
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
Tadepally Lakshmikanth,Shannon Burke,Talib Hassan Ali,Silvia Kimpfler,Francesco Ursini,Loredana Ruggeri,Marusca Capanni,Viktor Umansky,Annette Paschen,Antje Sucker,Daniela Pende,Veronika Groh,Roberto Biassoni,Petter Höglund,Masashi Kato,Kazuko Shibuya,Dirk Schadendorf,Andrea Anichini,Soldano Ferrone,Andrea Velardi,Klas Kärre,Akira Shibuya,Ennio Carbone,Francesco Colucci +23 more
TL;DR: It is shown that human melanoma cell lines derived from LN metastases express ligands for natural cytotoxicity receptors (NCRs) and DNAX accessory molecule-1 (DNAM-1), two emerging NK cell receptors key for cancer cell recognition, but not NK group 2 member D (NKG2D).